HealingPreclinicalAnimal Studies

BPC-157

Also known as Body Protection Compound-157, Pentadecapeptide BPC 157

A synthetic peptide derived from a protein found in human gastric juice. Extensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract.

Preclinical - FDA Category 2 (restricted from compounding as of September 2023)

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

250-500 mcg twice daily

Frequency

1-2x daily

Duration

4-12 weeks

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 250-500 mcg twice daily via Subcutaneous injection, 1-2x daily. Dose range: 200-1,000 mcg per day total. Duration: 4-12 weeks.

Timing & Administration

Administer via Subcutaneous injection. Frequency: 1-2x daily.

Mechanism of Action

Modulates nitric oxide signaling, stimulates new blood vessel development, upregulates growth hormone receptors, engages dopaminergic pathways, and enhances collagen synthesis for accelerated tendon-to-bone healing.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical - FDA Category 2 (restricted from compounding as of September 2023).

Side Effects & Safety

Important Warnings

  • Caution with MCAS or histamine sensitivity
  • Restricted from compounding as of September 2023.
Nausea
dizziness
injection site reactions
fatigue
headache
potential histamine release
possible tumor promotion concerns from angiogenesis

References

No references available.